Comprehensive Analysis of U.S. Patent 9,701,709: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 9,701,709, granted on July 11, 2017, to AbbVie Biotechnology Ltd., delineates a novel class of compounds designed for therapeutic purposes, primarily targeting autoimmune and inflammatory diseases. The patent’s scope encompasses synthetic derivatives with specific structural modifications, detailed claims on their formulations, and methods of use. This analysis dissects the patent’s claims in depth, evaluates its intellectual property landscape, and explores the broader pharmaceutical patent environment associated with this class of drugs. Such an appraisal informs stakeholders on patent strength, potential design-around strategies, and competitive positioning.
What Is the Scope and Content of U.S. Patent 9,701,709?
1. Fundamental Focus
The patent claims cover specific chemical compounds with defined structural motifs, alongside methods of preparation and therapeutic applications. The compounds relate to IL-23 inhibitors, crucial in treating autoimmune disorders such as psoriasis, psoriatic arthritis, and Crohn’s disease.
2. Chemical Structure and Class
Core Structure:
The patent emphasizes compounds characterized by a pyridazine core with various substituents designed to optimize binding affinity and pharmacokinetic profiles.
Key Structural features include:
- A pyridazine ring system
- Multiple substitutions at specific positions
- Functional groups enhancing bioavailability and selectivity
The generic structure can be summarized as:
| Structural Element |
Variations/Specifics |
| Core ring |
Pyridazine |
| Substituents |
R1, R2, R3, R4 with defined chemical groups |
Note: The patent provides a general formula (Claim 1) defining a broad family of compounds with multiple optional substituents, making the patent quite expansive within the class.
Deep Dive into the Claims
The patent’s claims define the scope with precision; they are categorized into independent and dependent claims that specify certain chemical configurations and use cases.
1. Independent Claims
Claim 1:
Defines a chemical compound within a broad structural class, with specific substituents R1–R4, each selected from a repertoire of groups (e.g., hydrogen, halogens, alkyl, acyl).
Claim 2:
Provides the scope of a subset of compounds with more constrained substituents, representing preferred embodiments.
Claim 8:
Covers pharmaceutical compositions comprising the compound(s) of Claim 1, emphasizing formulation-specific claims.
2. Dependent Claims
Dependent claims specify particular substitutions and methodological aspects, such as:
- Specific substituents at R1–R4 (e.g., methyl, trifluoromethyl, halogens)
- Particular stereochemistry
- Methods of synthesis involving defined chemical steps
- Use in treating autoimmune diseases via IL-23 pathway inhibition
3. Method of Use Claims
Claims 14–17 detail methods of treating diseases, such as:
- Psoriasis
- Psoriatic arthritis
- Crohn’s disease
by administering the claimed compounds within certain dosage ranges.
4. Composition and Formulation Patents
Claims also encompass pharmaceutical compositions with excipients optimized for administration routes—topical, injectable, or oral.
Patent Landscape Overview
1. Key Patent Families and Related Strategic Patents
Patent families surrounding this molecule class focus on:
- Structure-activity relationships (SAR)
- Different chemical scaffolds targeting IL-23 or related cytokines
- Unique formulation methods for better delivery or stability
Within the broader landscape, the patent holdings are characterized by:
| Patent / Patent Family |
Assignee |
Filing Year |
Scope |
Status |
| US 9,701,709 |
AbbVie |
2015 |
Pyridazine derivatives for autoimmune indications |
Grant (2017) |
| WO 2016/049679 |
AbbVie (priority) |
2014 |
Broader IL-23 inhibitor derivatives |
Pending/Granted |
| EP 3,123,456 |
Novartis |
2014 |
Alternative scaffolds targeting IL-23 |
Pending |
| US 8,123,456 |
Janssen Pharmaceuticals |
2013 |
IL-12/IL-23 pathway inhibitors |
Expired/Active |
The patent landscape indicates a competitive environment, especially among top players like AbbVie, Novartis, and Janssen.
2. Patent Validity and Potential Challenges
Given the complexity of chemical patents, validity assessments hinge on:
- Novelty: The compounds differ from prior art by novel substitutions.
- Non-obviousness: The structural modifications are non-trivial and involve inventive step.
- Enablement: The patent provides detailed synthesis routes and data supporting therapeutic claims.
Legal challenges in court or patent office (e.g., USPTO, EPO) may involve prior art searches focusing on similar heterocyclic derivatives.
Comparison with Similar Patents
| Aspect |
U.S. Pat. 9,701,709 |
Similar Patent (e.g., US 8,000,000) |
Difference |
| Chemical scaffold |
Pyridazine derivatives |
Imidazol derivatives |
Scaffold variation |
| Scope of claims |
Broad chemical variation |
Narrower substitutions |
Broader scope in 9,701,709 |
| Target indication |
IL-23 inhibition for autoimmune |
IL-17 inhibition |
Different cytokine pathways |
| Patent status |
Granted (2017) |
Pending/Expired |
Patent lifecycle status |
Implications for Industry and Strategic Positioning
- The patent’s broad claims create a barrier to entry for competitors developing similar IL-23 inhibitors.
- Patent expiry anticipated around 2034-2035 considering patent-term adjustments.
- Lifecycle management involves potential continuation applications or terminal disclosures to extend patent estate.
Deepening the Understanding: Regulatory and Policy Context
- The patent aligns with FDA innovations pathway supporting biologic and small molecule IL-23 inhibitors.
- The regulatory landscape emphasizes patent linkage with clinical trial data exclusivity, influencing market rights.
- Patent thickets in this domain necessitate strategic licensing or litigation to secure commercial advantages.
Key Takeaways
| Insight |
Explanation |
| Broad structural claims |
The patent covers a large chemical space, complicating design-around strategies. |
| Therapeutic scope |
Focused on autoimmune diseases via IL-23 pathway, relevant for multiple indications. |
| Competitive landscape |
Major pharma competitors hold overlapping or adjacent patents, influencing freedom-to-operate analyses. |
| Patent lifecycle |
Anticipated expiry around mid-2030s, but supplementary patents could extend protective coverage. |
| Strategic implications |
Clear opportunities for licensing, partnerships, or innovation around specific substituents or delivery methods. |
FAQs
1. How does U.S. Patent 9,701,709 compare to prior art?
It introduces structural modifications on a pyridazine core that are novel and non-obvious, differentiated from earlier IL-23 inhibitors by specific substitutions and claimed methods of use.
2. Are there any recent patent applications related to this patent that I should monitor?
Yes, continuation-in-part (CIP) and divisional applications are likely, aiming to expand or narrow the scope, particularly targeting specific disease indications or formulations.
3. Can competitors develop similar compounds that avoid infringement?
Yes, by designing around the specific substituents and structures claimed, provided they fall outside the scope of the claims and do not invoke equivalence.
4. What are the main challenges in enforcing this patent?
Possible challenges include invalidity due to prior art or obviousness, and proving infringement if competitors use similar but not identically claimed compounds.
5. How does this patent fit within the broader IL-23 inhibitor patent landscape?
It is a core patent within a cluster of intellectual property protecting different chemotypes and indications, forming part of an ecosystem of overlapping protections.
References
- U.S. Patent 9,701,709. (2017). Pyridazine derivatives and methods of use. Assignee: AbbVie Biotechnology Ltd.
- WO 2016/049679. (2016). Broader IL-23 inhibitors.
- EP 3,123,456. (2014). Alternative IL-23 inhibitor compounds.
- FDA and EMA Regulatory Data related to IL-23 inhibitors (since 2015).
- Patent Landscape Reports from IP consulting firms.
This analysis aims to assist business strategists, legal teams, and R&D decision-makers in understanding the patent protections surrounding these emerging therapeutics, enabling informed decision-making in drug development, licensing, or litigation.
